Related Experiment Videos
[Radiation doses deriving from patients treated with (166)Ho-ferric hydroxide]
J Preitfellner1, C Pirich, P John
1Universitätsklinik für Nuklearmedizin, AKH Wien, Währinger Gürtel 18-20, A-1090 Wien, Osterreich. josef.preitfellner@akh-wien.ac.at
Nuklearmedizin. Nuclear Medicine
|December 12, 2003
Summary
Radiation doses from holmium-166 ferric hydroxide (166Ho-FH) injections for radiation synoviorthesis are minimal for medical staff and the public. Shielding devices do not significantly reduce radiation exposure in this treatment.
Area of Science:
- Nuclear Medicine
- Radiopharmacology
- Radiation Dosimetry
Context:
- Radiation synoviorthesis is a treatment for joint inflammation.
- Holmium-166 ferric hydroxide (166Ho-FH) is a radiopharmaceutical used in this procedure.
- Accurate radiation dose estimation is crucial for patient safety and regulatory compliance.
Purpose:
- To estimate radiation doses to medical personnel and the public from 166Ho-FH administered for radiation synoviorthesis.
- To evaluate the effectiveness of radiation protection devices during the procedure.
Summary:
- 16 patients received approximately 900 MBq of 166Ho-FH into the knee joint.
- Dose rates were measured at various distances, and whole-body and finger doses for staff were recorded.
- Calculated radiation exposure for medical personnel and the public was found to be well below annual dose limits.
Impact:
- The study provides essential data for the safe clinical application of 166Ho-FH in radiation synoviorthesis.
- Findings indicate that additional shielding for syringes offers no significant benefit in reducing radiation exposure.
- This research supports the continued use of 166Ho-FH while ensuring radiation safety standards are met.